Journals / Turkish Journal of Hematology / 2009 / Cilt: 26 - Sayı: 3

Siprofloksasin: Demir yüklenmesi için yeni bir terapötik ajan mı?

Ciprofloxacin: A novel therapeutic agent for iron overload?

Pages
114–117
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: Administration of ciprofloxacin may help to decrease the burden of parenteral administration, thereby improving compliance and also the life expectancy of thalassemic patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Major thalassemia is one of the hematological diseases requiring multiple blood transfusions, which results in iron overload in the liver, heart and other organs.
📊
Key Findings & Data:Ciprofloxacin (7 or 14 mg/kg per day) was administered simultaneously with iron (0.03 g/kg per day) or after one-month administration of iron.
💡
Conclusion & Impact:CONCLUSION: Administration of ciprofloxacin may help to decrease the burden of parenteral administration, thereby improving compliance and also the life expectancy of thalassemic patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Sıçan · Wistar · Demir aşırı yüklemesi

Abstract

OBJECTIVE: Major thalassemia is one of the hematological diseases requiring multiple blood transfusions, which results in iron overload in the liver, heart and other organs. Current iron chelation therapy consists of intravenous (IV) deferoxamine and oral deferasirox and deferiprone. Although these chelators are effective, many side effects are reported. In the present study, the iron-chelating effect of ciprofloxacin with good oral absorption was investigated. METHODS: Thirty male albino Wistar rats were used for the study. Ciprofloxacin (7 or 14 mg/kg per day) was administered simultaneously with iron (0.03 g/kg per day) or after one-month administration of iron. Ciprofloxacin effect on iron absorption in the liver and heart was studied carefully using atomic absorption. RESULTS: A significant decrease in the liver and heart iron following the ciprofloxacin (14 mg/kg per day) administration was observed, when compared with the control group. This ciprofloxacin-induced tissue iron depletion was more pronounced when it was administered simultaneously with iron, when it was administered for a longer duration (2 months rather than 1 month) and when it was given in higher doses (14 mg/kg per day). CONCLUSION: Administration of ciprofloxacin may help to decrease the burden of parenteral administration, thereby improving compliance and also the life expectancy of thalassemic patients.

Özet

AMAÇ: Talasemi majör, karaciğer, kalp ve diğer organlarda demir yüklenmesiyle sonuçlanan, çoklu kan transfüzyonları gerektiren hematolojik hastalıklardan biridir. Güncel demir şelasyon tedavisi, intravenöz (IV) defroksamin ve oral deferasiroks ve deferipron uygulamasını içermektedir. Bu şelatörlerin etkili olmalarına karşın, birçok yan etkileri bulunmaktadır. Bu çalışmada, iyi oral absorbsiyonlu siprofloksasinin demir bağlayıcı etkileri araştırılmıştır. YÖNTEMLER: Bu çalışmada 30 erkek Wistar sıçanı kullanıldı. Siprofloksasin (7 veya 14 mg/kg/gün), demirle aynı zamanda (0.03 g/kg/gün) veya 1 aylık demir uygulaması sonrası uygulanmıştır. Siprofloksasinin karaciğer ve kalpteki demir absorbsiyonu üzerine olan etkisi atomik absorbsiyon kullanılarak dikkatlice çalışılmıştır. BULGULAR: Kontrol grubuyla karşılaştırıldığında, siprofloksasin uygulamasını (14 mg/kg/gün) takiben karaciğer ve kalp demirinde anlamlı bir düşüş gözlenmiştir. Siprofloksasinle indüklenen bu doku demir deplesyonu yüksek dozda daha belirgindir. SONUÇ: Siprofloksasin uygulaması, uyumluluğu ve ayrıca talasemik hastaların yaşam beklentisini artırarak, parenteral uygulama yükünü azaltmaya yardımcı olabilir.

🔖

Cite This Article

ELMI, M., MOGHADDAM-RAHIMI, P., ABDI, K., SHAFE-ARDESTANI, M., MAHMOUDIAN, M. (2009). Siprofloksasin: Demir yüklenmesi için yeni bir terapötik ajan mı?. Turkish Journal of Hematology, Cilt: 26 - Sayı: 3, 114–117. https://ajindex.com/articles/413366

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Se’chau R, Krebs- Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomized, double-blind, placebocontrolled, dose-escalation trial. Lancet 2003;361:1597-602
  2. Dubey AP, Sudha S, Parakh A. Deferasirox: the new oral iron chelator. Indian Pediatr. 2007;44:603-7
  3. Issopoulos PB. Spectrophotometric determination of trace amounts of iron (ΙΙΙ) with norfloxacin as complexing reagent. Analyst 1989;189:627-30
  4. Eboka CJ, Aigbavboa SO, Akerele JO. Colorimetric determination of fluoroquinolones. J Antimicrob Chemother 1997;39:639-41
  5. Nagaralli BS, Seetharamappa J, Melwanki MB. Sensitive spectrophotometric methods for the determination of amoxicillin, ciprofloxacin and piroxicam in pure and pharmaceutical formulations. Pharm Biomed Anal 2002;29:859-64
  6. Lehto P, Kivisto KT, Pertti JN. The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol 1994;37:82-5
  7. Kara M, Hasinoff BB, Mckay DW, Campell NR. Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 1991;31:257-61
  8. Kang JO, Jones C, Brothwell B. Toxicity associated with iron overload found in haemochromatosis: possible mechanism in a rat model. Clin Lab Sci 1998;11:350-4
  9. Schwartz KA, Fisher J, Adams ET. Morphologic investigations of the guinea pig model of iron overload. Toxicol Pathol 1993;21:311-20
  10. Chambers HF. Sulfonamides, trimethoprim and quinolones. In: Katzung BG, editor. Basic and Clinical Pharmacology. San Francisco, CA, USA: Lange Publication, 2007: 763-70
  11. FDA ALERT [7/8/2008]: (http: //www.fda.gov/medwatch/safety/ 2008/safety08.htm#Fluoroquinolone).